$BBIO News

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

What BridgeBio Pharma Doubters Missed

BridgeBio Pharma (BBIO) Draws Fresh Attention, Is The Pullback A Valuation Opportunity?

Where Does BridgeBio Pharma (BBIO) Value Sit After Trial Wins?

How Pipeline Progress Will Impact BridgeBio Pharma (BBIO) Investors

BridgeBio Pharma (BBIO) Unveils Acoramidis Data As Rare Disease Pipeline Nears Key Reviews

Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

BridgeBio's Encaleret Shows Symptoms, Bone Turnover Improvements in Phase 3 Trial in ADH1

Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care

Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations

Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1

Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day